Published in Transl Oncol on May 01, 2009
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell (2014) 2.14
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10
Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res (2010) 1.97
Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell (2014) 1.79
The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci (2011) 1.66
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J (2011) 1.49
Biomarker based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. Cancer Res (2017) 1.42
Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol (2010) 1.40
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A (2010) 1.39
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. Sci Transl Med (2015) 1.27
Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med (2015) 1.23
In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol (2012) 1.21
MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3). J Biol Chem (2014) 1.17
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One (2015) 1.11
Life in the fast lane: mammalian disease models in the genomics era. Cell (2012) 1.08
The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn (2012) 1.02
Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas. Oncotarget (2011) 0.95
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proc Natl Acad Sci U S A (2014) 0.93
Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner. ACS Nano (2014) 0.93
Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev (2011) 0.92
On the origin of glioma. Ups J Med Sci (2012) 0.92
Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. Oncotarget (2014) 0.92
Identification of global alteration of translational regulation in glioma in vivo. PLoS One (2012) 0.91
Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. Oncotarget (2015) 0.89
Contribution of tumor heterogeneity in a new animal model of CNS tumors. Mol Cancer Res (2014) 0.88
PDGF in gliomas: more than just a growth factor? Ups J Med Sci (2012) 0.88
Brain stem cells as the cell of origin in glioma. World J Stem Cells (2014) 0.88
F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS One (2013) 0.87
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget (2015) 0.87
Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression. Cancer Res (2014) 0.86
Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. J Oncol (2010) 0.86
Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol (2015) 0.85
Corticosteroids compromise survival in glioblastoma. Brain (2016) 0.84
Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma. Neuro Oncol (2016) 0.82
Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma. Front Oncol (2015) 0.82
Metabolic profiling of dividing cells in live rodent brain by proton magnetic resonance spectroscopy (1HMRS) and LCModel analysis. PLoS One (2014) 0.82
High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe. Theranostics (2016) 0.81
Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. Neoplasia (2012) 0.81
The probable cell of origin of NF1- and PDGF-driven glioblastomas. PLoS One (2011) 0.81
What underlies the diversity of brain tumors? Cancer Metastasis Rev (2013) 0.81
Review: insights gained from modelling high-grade glioma in the mouse. Neuropathol Appl Neurobiol (2012) 0.80
Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H. Neurotherapeutics (2014) 0.80
Suppression of autophagy impedes glioblastoma development and induces senescence. Autophagy (2016) 0.80
Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. Oncotarget (2012) 0.80
Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. Proc Natl Acad Sci U S A (2015) 0.80
The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics. Oncogene (2015) 0.79
Low Concentration Microenvironments Enhance the Migration of Neonatal Cells of Glial Lineage. Cell Mol Bioeng (2012) 0.79
Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma. J Vis Exp (2015) 0.79
Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. Neoplasia (2016) 0.78
Bionanotechnology and the future of glioma. Surg Neurol Int (2015) 0.78
Ganglioside GD3 Enhances Invasiveness of Gliomas by Forming a Complex with Platelet-derived Growth Factor Receptor α and Yes Kinase. J Biol Chem (2015) 0.77
Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma. J Nucl Med (2016) 0.77
Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev (2017) 0.77
Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathol (2016) 0.76
Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol (2017) 0.75
Glioma Stem Cells but Not Bulk Glioma Cells Upregulate IL-6 Secretion in Microglia/Brain Macrophages via Toll-like Receptor 4 Signaling. J Neuropathol Exp Neurol (2016) 0.75
Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer. PLoS One (2017) 0.75
Overview of Transgenic Glioblastoma and Oligoastrocytoma CNS Models and Their Utility in Drug Discovery. Curr Protoc Pharmacol (2016) 0.75
Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles. J Nucl Med (2016) 0.75
Development of genetically flexible mouse models of sarcoma using RCAS-TVA mediated gene delivery. PLoS One (2014) 0.75
Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival. Oncotarget (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (1985) 8.23
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Radial glia cells are candidate stem cells of ependymoma. Cancer Cell (2005) 5.21
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53
CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res (1996) 4.42
Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene (2003) 3.83
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res (1991) 3.16
Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res (1992) 3.15
Gene expression profiling identifies molecular subtypes of gliomas. Oncogene (2003) 3.13
Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet (2001) 3.13
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res (2006) 2.68
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 2.45
Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res (1988) 2.28
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res (1994) 2.28
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol (2005) 2.24
Identification of neural stem cells in the adult vertebrate brain. Brain Res Bull (2002) 2.21
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res (2006) 2.01
Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys (1993) 1.99
Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg (2006) 1.93
Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res (2008) 1.60
Incidence of gliomas by anatomic location. Neuro Oncol (2007) 1.55
Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett (2005) 1.53
Biology and treatment of malignant glioma. Semin Oncol (2000) 1.51
Brainstem gliomas in adults: prognostic factors and classification. Brain (2001) 1.46
Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci U S A (1994) 1.39
Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery (1998) 1.32
Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res (1994) 1.29
Primary cerebellar glioblastoma multiforme. Diagn Interv Radiol (2005) 1.22
Tumorigenesis in the brain: location, location, location. Cancer Res (2007) 1.09
MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia (2002) 1.08
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol (1994) 1.06
Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol (2003) 1.00
Using mice to decipher the molecular genetics of brain tumors. Neurosurgery (2003) 0.99
Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. J Neurooncol (2005) 0.97
Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors. J Neurooncol (2001) 0.95
Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer (2002) 0.94
Selection bias in clinical trials of anaplastic glioma. Ann Neurol (1989) 0.94
CNTF and its receptor subunits in human gliomas. J Neurooncol (1999) 0.86
Genetic modeling of glioma formation in mice. Brain Pathol (2002) 0.83
Cholesteatoma of the middle ear in human patients. An ultrastructural study. Arch Otolaryngol (1976) 0.79
Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science (2013) 6.29
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell (2009) 4.94
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell (2003) 3.68
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature (2006) 2.69
Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res (2006) 2.68
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell (2012) 2.50
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 2.45
Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res (2004) 2.36
The brain tumor microenvironment. Glia (2011) 2.13
Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem (2004) 2.07
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res (2006) 2.01
Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res (2010) 1.97
Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene (2004) 1.96
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82
Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res (2002) 1.82
Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med (2004) 1.76
Notch signaling enhances nestin expression in gliomas. Neoplasia (2006) 1.73
Radiation resistance and stem-like cells in brain tumors. Cancer Cell (2006) 1.70
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell (2010) 1.68
The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg (2012) 1.67
Cancer stem cells and survival pathways. Cell Cycle (2008) 1.66
The brain tumor microenvironment. Glia (2012) 1.66
Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol (2009) 1.66
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res (2005) 1.65
Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 1.61
Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res (2008) 1.60
p27 deficiency is associated with migration defects in PDGF-expressing gliomas in vivo. Cell Cycle (2010) 1.59
Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene (2004) 1.58
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett (2005) 1.53
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J (2011) 1.49
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res (2005) 1.47
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res (2005) 1.46
Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. J Neurosurg Spine (2010) 1.45
miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS One (2012) 1.44
c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia (2003) 1.40
Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. J Neurosci (2009) 1.38
Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. PLoS One (2011) 1.37
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. Mol Syst Biol (2012) 1.36
DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res (2011) 1.33
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
The perivascular niche microenvironment in brain tumor progression. Cell Cycle (2010) 1.30
Glioma formation, cancer stem cells, and akt signaling. Stem Cell Rev (2008) 1.30
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. Proc Natl Acad Sci U S A (2002) 1.26
An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest (2011) 1.25
The ABCG2 resistance network of glioblastoma. Cell Cycle (2009) 1.24
KRIT1/cerebral cavernous malformation 1 protein localizes to vascular endothelium, astrocytes, and pyramidal cells of the adult human cerebral cortex. Neurosurgery (2004) 1.24
A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J Exp Med (2007) 1.22
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol (2008) 1.18
p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev (2003) 1.16
Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. Cancer Res (2012) 1.15
Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. Neurosurg Clin N Am (2007) 1.15
PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One (2013) 1.14
Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. J Exp Med (2009) 1.14
Krev1 interaction trapped-1/cerebral cavernous malformation-1 protein expression during early angiogenesis. J Neurosurg (2004) 1.14
The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia (2005) 1.12
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. J Neurooncol (2009) 1.11
Incorporating molecular tools into clinical trials and treatment for gliomas? Curr Opin Neurol (2007) 1.11
Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol (2004) 1.09
MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia (2002) 1.08
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol (2012) 1.07
MYC expression promotes the proliferation of neural progenitor cells in culture and in vivo. Neoplasia (2002) 1.06
Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS One (2012) 1.03
Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res (2007) 1.02
Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization. Cancer Res (2009) 1.01
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol (2011) 1.00
Stereotactic laser induced thermotherapy (LITT): a novel treatment for brain lesions regrowing after radiosurgery. J Neurooncol (2013) 1.00
The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS One (2010) 0.99
Using mice to decipher the molecular genetics of brain tumors. Neurosurgery (2003) 0.99
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J (2011) 0.98
Stem cells and brain cancer. Exp Cell Res (2005) 0.98
Complement receptor of the Ig superfamily enhances complement-mediated phagocytosis in a subpopulation of tissue resident macrophages. J Immunol (2008) 0.97
Astrocyte differentiation states and glioma formation. Cancer J (2003) 0.96
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. PLoS One (2012) 0.96
Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma. Int J Radiat Oncol Biol Phys (2011) 0.96